Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Activated clotting time tube malfunction: a rare cause of heparin overdose.

Kumar B, Badamali AK.

Ann Card Anaesth. 2013 Apr-Jun;16(2):155-6. doi: 10.4103/0971-9784.109779. No abstract available.

2.

Emergency reversal of heparin overdose in a neurosurgical patient guided by thromboelastography.

Figueiredo S, Vigué B, Benhamou D, Duranteau J.

Br J Anaesth. 2013 Aug;111(2):303-4. doi: 10.1093/bja/aet245. No abstract available.

PMID:
23858079
3.

Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.

Maul TM, Wolff EL, Kuch BA, Rosendorff A, Morell VO, Wearden PD.

Pediatr Crit Care Med. 2012 Nov;13(6):e363-71. doi: 10.1097/PCC.0b013e31825b582e.

PMID:
22940857
4.

Pediatric enoxaparin overdose: more attention to thromboelastography monitoring.

Pittalis A, Tuccillo ML, Savron F, Schember C, Morri D, Dell'Oste C.

Minerva Anestesiol. 2013 Oct;79(10):1203-4. Epub 2013 Apr 5. No abstract available.

PMID:
23558766
5.

Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro.

Despotis GJ, Filos KS, Levine V, Alsoufiev A, Spitznagel E.

Anesth Analg. 1996 Jun;82(6):1126-31.

PMID:
8638779
6.

[Effects of aprotinin on heparinized whole blood activated clotting time and whole blood prothrombin time].

Wen Z, Zhu F, He X, Xiong S, He S.

Hunan Yi Ke Da Xue Xue Bao. 1997;22(4):304-6. Chinese.

PMID:
9868081
7.

Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy.

Kurec AS, Morris MW, Davey FR.

Ann Clin Lab Sci. 1979 Nov-Dec;9(6):494-500.

PMID:
518012
8.

Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations.

Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, Cox JL, Lappas DG.

J Thorac Cardiovasc Surg. 1994 Dec;108(6):1076-82.

PMID:
7983877
9.

Heparin resistance, antithrombin III treatment, and activated clotting time values.

Kanbak M.

Anesth Analg. 1998 Nov;87(5):1215. No abstract available.

PMID:
9806721
10.

Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.

Ganter MT, Monn A, Tavakoli R, Genoni M, Klaghofer R, Furrer L, Honegger H, Hofer CK.

Eur J Cardiothorac Surg. 2006 Aug;30(2):278-84. Epub 2006 Jul 7.

PMID:
16828293
11.

Coagulation protein function VI: augmentation of anticoagulant function by acetaldehyde-treated heparin.

Brecher AS, Hellman K, Basista MH.

Dig Dis Sci. 1999 Jul;44(7):1349-55.

PMID:
10489917
12.

The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery.

Martindale SJ, Shayevitz JR, D'Errico C.

J Cardiothorac Vasc Anesth. 1996 Jun;10(4):458-63.

PMID:
8776637
13.

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A.

Thromb Haemost. 2010 Jun;103(6):1116-27. doi: 10.1160/TH09-11-0758. Epub 2010 Mar 29. Review.

PMID:
20352166
14.
15.

Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.

Guzzetta NA, Monitz HG, Fernandez JD, Fazlollah TM, Knezevic A, Miller BE.

Anesth Analg. 2010 Jul;111(1):173-9. doi: 10.1213/ANE.0b013e3181e13470. Epub 2010 Jun 2.

PMID:
20519414
16.

Rational approach to use of heparin during cardiac catheterization in children.

Grady RM, Eisenberg PR, Bridges ND.

J Am Coll Cardiol. 1995 Mar 1;25(3):725-9.

17.

Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery.

Lemmer JH Jr, Despotis GJ.

J Thorac Cardiovasc Surg. 2002 Feb;123(2):213-7.

18.

Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.

Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH.

Anesth Analg. 1998 Oct;87(4):781-5.

PMID:
9768770
19.

Research review: use of activated clotting time to monitor heparin therapy in coronary patients.

Noureddine SN.

Am J Crit Care. 1995 Jul;4(4):272-7; quiz 278-9. Review.

PMID:
7663590
20.

Preventing errors relating to commonly used anticoagulants.

[No authors listed]

Sentinel Event Alert. 2008 Sep 24;(41):1-4. No abstract available.

PMID:
18814386

Supplemental Content

Support Center